InvestorsHub Logo
Followers 5
Posts 719
Boards Moderated 0
Alias Born 08/27/2018

Re: Foxwoods Man post# 17640

Wednesday, 01/09/2019 8:29:26 AM

Wednesday, January 09, 2019 8:29:26 AM

Post# of 43764
What's interesting to me about this, is this affirms a fast track and approval, which is certainly awesome compared to 75M cap. But in the background we've heard a few things which this information contrasts with.

1. "We're the first and only." Maybe back in the day when things started, but with the arb and trial issue, not so much. However, if it's approved as a FIRST LINE SOC, then yes. This is a unique use of it

2. Were Merck and Co behind the backdoor payments that potentially stole and forced the hand of the CRO to screw over MK/CVM??? We'll never know, but my suspicion is a big YES. Although it's horribly fraudulent, this seems logical

3. If we're not a first and only, then what are we? A competition??? What's the competition worth? To me I'm grateful that this legitimizes MK as a competition. May it play down the value a tad of not being "first and only?" Maybe, but I could see Merck and Co offering a few B perhaps avoid competition.... That's better than 75M

4. What are the uses of this Merck drug, is it the first line of defense, and is it being used for our hopeful high dollar revenue? By the advertising, it doesn't look like it.

However, the bottom line is, our stock is sooo low, it'll still grow a lot on the approval news. These other factors making "to the moon of $300 per share" may not be as believable. But, 75-100 minimum can still be on the horizon, especially knowing that the competition is in play.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News